Fay Lin, Senior Editor of Technology at Genetic Engineering and Biotechnology News, shared a post on LinkedIn:
“It’s that time again for our virtual event, ‘The State of AI in Drug Discovery’ from GEN (Genetic Engineering and Biotechnology News) streaming on October 29th!
In 2024, the inaugural ‘The State of AI in Drug Discovery’ drew in a record audience. This year’s summit provides a platform for an outstanding group of researchers and entrepreneurs to showcase the latest advances, applications and challenges of the deployment of AI across therapeutic development.
Check out our dynamic program!
- A featured presentation with Bo Wang (Xaira Therapeutics) on the promise of multimodal AI for healthcare
- The democratization of small molecule drug discovery with the developers of Boltz-2, Gabriele Corso, Regina Barzilay (Massachusetts Institute of Technology), and Najat Khan, PhD (Recursion)
- Evolving industry trends across the AI therapeutic landscape with Derek Lowe (author of ‘In the Pipeline’), Molly Gibson (Flagship Pioneering), and Stacie Calad-Thomson, PhD (NVIDIA)
- Building the virtual cell with Theofanis Karaletsos (Chan Zuckerberg Initiative), Emma Lundberg (Stanford University), Hani Goodarzi (Arc Institute), and Ron Alfa, MD, PhD (NOETIK)
- What’s next for AI in protein design with Surge Biswas (Nabla Bio), Tharindi Hapuarachchi, PhD (Generate: Biomedicines), and Oliver Vince (Basecamp Research)
- Breakout sessions from our event sponsors, Revvity Signals, Benchling, and Telesis Bio
Registration is free! See you there!”
Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared this post, adding:
“Amazing program, Fay Lin, PhD. These featured speakers are elite. I can’t wait for this one.”
More posts featuring Douglas Flora.